{"schema":"hottub-news/story/v1","story":"st_2lzhieoznxlwzptntqnq","title":"Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk","title_en":null,"outlets":3,"brief":null,"page":"https://hottub.news/stories/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-2lzhieoznx","count":4,"items":[{"id":"n_z3k73zyxjxfviutsn52a","seq":1124203,"kind":"article","title":"Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk","url":"https://www.finanznachrichten.de/nachrichten-2026-10/69729883-monte-rosa-therapeutics-inc-monte-rosa-therapeutics-announces-positive-results-for-mrt-8102-in-gforce-1-phase-1-study-showing-normalization-of-key-399.htm","published":"2026-10-01T11:30:39Z","seen":"2026-10-01T11:30:39Z","lang":"en","country":"DE","source":{"id":"finanznachrichten.de","name":"finanznachrichten.de","domain":"finanznachrichten.de","outlet":{"wikidata":"Q1408247","name":"Finanznachrichten.de","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","politics","health","business"],"authors":["GlobeNewswire (Europe)"],"story":"st_2lzhieoznxlwzptntqnq","category":"health","category_p":0.6000000238418579,"sentiment":"positive","tone":0.019999999552965164,"political":0.019999999552965164},{"id":"n_pkrc3gsxgflhqntprhaq","seq":1118307,"kind":"press_release","title":"Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk","url":"https://www.globenewswire.com/news-release/2026/10/01/3372740/0/en/monte-rosa-therapeutics-announces-positive-results-for-mrt-8102-in-gforce-1-phase-1-study-showing-normalization-of-key-pathogenic-drivers-of-ascvd-in-subjects-with-elevated-cvd-ris.html","summary":"Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study","published":"2026-10-01T11:00:00Z","seen":"2026-10-01T11:03:46Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:glue","us61225m1027"],"entities":[{"id":"Q115011580","name":"Monte Rosa Therapeutics","type":"org"},{"id":"Q1444550","name":"arteriosclerotic heart disease","type":"other"},{"id":"Q389735","name":"cardiovascular disease","type":"other"}],"story":"st_2lzhieoznxlwzptntqnq","category":"health","category_p":0.6800000071525574,"sentiment":"positive","tone":0.44999998807907104,"political":0.019999999552965164},{"id":"n_mirnzpl3jwiimqtcjy6q","seq":1056890,"kind":"article","title":"Monte Rosa Set To Report MRT-8102 Phase 1 Data In Cardiovascular Risk Study Today; Stock Up","url":"https://www.rttnews.com/3695558/monte-rosa-set-to-report-mrt-8102-phase-1-data-in-cardiovascular-risk-study-today-stock-up.aspx","published":"2026-10-01T04:50:00Z","seen":"2026-10-01T05:10:03Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["health","economy","business"],"story":"st_2lzhieoznxlwzptntqnq","category":"economy-business","category_p":0.6100000143051147,"category2":"health","sentiment":"neutral","tone":-0.10999999940395355,"political":0.009999999776482582},{"id":"n_2lzhieoznxlwzptntqnq","seq":992785,"kind":"press_release","title":"Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk","url":"https://www.globenewswire.com/news-release/2026/09/30/3372369/0/en/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk.html","published":"2026-09-30T20:01:00Z","seen":"2026-09-30T20:15:36Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:glue","us61225m1027"],"entities":[{"id":"Q115011580","name":"Monte Rosa Therapeutics","type":"org"}],"story":"st_2lzhieoznxlwzptntqnq","category":"health","category_p":0.8399999737739563,"sentiment":"neutral","tone":0.23999999463558197,"political":0.029999999329447746}]}